1.	A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO27952, 2012-000660-22, NCT01641939
2.	A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO28231, 2012-001628-37, NCT01702571
3.	A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO27938, 2012-002018-37, NCT01772472
4.	Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab Phase: Phase II Type: Treatment Status: Active Age: 20 to 70 Sponsor: Other Protocol IDs: OMC-BC01, UMIN000006288, NCT01432223
5.	HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 Phase: Phase II Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IJBMNTDM1, 2011-005437-39, NCT01565200
6.	Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 60 and over Sponsor: Other Protocol IDs: EORTC-75111-10114, 2011-006342-32, NCT01597414
7.	A Combination Study of Trastuzumab Emtansine And Capecitabine in Patients With Breast Cancer Or Gastric Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO28230, 2012-001547-46, NCT01702558
8.	A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: WSG-AM06/ADAPT HER2+/HR+, NCT01745965
9.	T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 13-048, NCT01853748
10.	A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO25499, 2011-004591-10, NCT01513083
11.	Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 7900, NCI-2013-00552, P30CA015704, NCT01816035